Oncothyreon Inc. (Nasdaq: ONTY) today announced the initiation of a Phase 1/2 trial of PX-866 in combination with vemurafenib (Zelboraf) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE